New perspectives on immunomodulatory therapy for bacteraemia and sepsis

International Journal of Antimicrobial Agents

Volumn 36, Issue SUPPL. 2, 2010, Pages

  Opal, Steven M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Immunomodulation; Lipopolysaccharide; Sepsis; Sepsis induced immunosuppression; Septic shock

Indexed keywords

FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 15; INTERLEUKIN 7; PATTERN RECOGNITION RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR;

ACINETOBACTER; ARTICLE; BACTEREMIA; BACTERIAL VIRULENCE; CANDIDIASIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; INFLAMMATION; INTENSIVE CARE; NONHUMAN; PRIORITY JOURNAL; SECONDARY INFECTION; SEPSIS; SEPTIC SHOCK; STENOTROPHOMONAS;

BACTEREMIA; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; OPPORTUNISTIC INFECTIONS; SEPSIS;

EID: 78650211572     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.11.008     Document Type: Article

References (29)

1. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit Care Med 29 2001 1303 1310
2. R.P. Dellinger, M.M. Levy, J.M. Carlet, J. Bion, M.M. Parker, and R. Jaeschke for the International Surviving Sepsis Campaign Guidelines Committee. Surviving Sepsis Campaign: International guidelines for the management of severe sepsis and septic shock Crit Care Med 36 2008 296 327
3. G.S. Martin, D.M. Mannino, S. Eaton, and M. Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554
4. S.M. Opal, and T. Calandra Antibiotic usage and resistance. Gaining or losing ground on infections in critically ill patients JAMA 302 2009 2367 2368
5. S.M. Opal The host response to endotoxin, anti-LPS strategies and the management of severe sepsis Int J Med Microbiol 297 2007 365 377
6. S. Akira, and K. Takeda Toll-like receptor signaling Nat Rev Immunol 4 2004 499
7. K. Takeda Evolution and integration of innate immune recognition systems: the Toll-like receptors J Endotoxin Res 11 2005 51
8. T. van der Poll, and S.M. Opal Host-pathogen interactions in sepsis Lancet Infect Dis 8 2008 32 43
9. I. Cinel, and S.M. Opal Molecular biology of inflammation and sepsis: a primer Crit Care Med 37 2009 291 304
10. S. Sriskandan, M. Ferguson, V. Elliot, L. Faulkner, and J. Cohen Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation J Antimicrob Chemother 58 2006 117 124
11. B. Beutler Inferences, questions and possibilities in Toll-like receptor signaling Nature 430 2004 257 263
12. M. Levi, and S.M. Opal Coagulation abnormalities in critically ill patients Crit Care 10 2006 222 228
13. M. Riewald, R.J. Petrovan, A. Donner, B.M. Mueller, and W. Ruf Activation of endothelial cell protease activated receptor 1 by the protein C pathway Science 296 2002 1880 1882
14. S.R. Coughlin Thrombin signaling and protease-activated receptors Nature 407 2000 258 264
15. R.S. Hotchkiss, and I.E. Karl The pathophysiology and treatment of sepsis N Engl J Med 348 2003 138 150
16. R.S. Hotchkiss, C.M. Coopersmith, J.E. McDunn, and T.A. Ferguson Tilting toward immunosuppression Nat Med 15 2009 496 497
17. R.S. Hotchkiss, and D.W. Nicholson Apoptosis and caspases regulate death and inflammation in sepsis Nat Rev Immunol 6 2006 813 822
18. M.R. Osuchowski, K. Welch, J. Siddiqui, and D.G. Remick Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality J Immunol 177 2006 1967 1974
19. A. Kalil A silent killer: Cytomegalovirus infection in the immunocompromised critically ill patient Crit Care Med 36 2008 3261 3264
20. M. Ziemann, Sedemund-Adib, R. ReiBland, P. Schmucker, and H. Henning Increased mortality in long-term intensive care patients with active cytomegalovirus infection Crit Care Med 36 2008 3145 3150
21. T. Okazaki, and T. Honjo The PD-1-PD-L pathway in immunological tolerance Trends Immunol 27 2006 195 201
22. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Ann Rev Immunol 26 2008 677 704
23. X. Huang, F. Venet, Y.L. Wang, A. Lepape, Z. Yuan, and Y. Chen PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis Proc Natl Acad Sci U S A 106 2009 6303 6308
24. C. Meisel, J.C. Schefold, R. Pschowski, T. Baumann, K. Hetzger, and J. Gregor Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression. A double-blind, randomized, placebo-controlled multicenter trial Am J Respir Crit Care Med 180 2009 640 648
25. B.C. Trapnell A novel biomarker-guided immunomodulatory approach for the therapy of sepsis Am J Respir Crit Care Med 180 2009 585 587
26. N.C. Kaneider, A. Agarwal, A.J. Leger, and A. Kuliopoulos Reversing systemic inflammatory response syndrome with chemokine receptor pepducins Nat Med 103 2005 15564 15569
27. F. Venet, J. Bohé, A.L. Debard, J. Bienvenu, A. Lepape, and G. Monneret Both percentage of gamma delta T lymphocytes and CD3 expression are reduced during septic shock Crit Care Med 33 2005 2836 2840
28. K. Laudanski, C. Miller-Graziano, W. Xiao, M.N. Mindrinos, D.R. Richards, and A. De Cell-specific expression and pathway analysis reveal alterations in trauma-related human T cell and monocyte pathways Proc Natl Acad Sci U S A 103 2006 15564 15569
29. M.M. Levy, R.P. Dellinger, S.R. Townsend, W.T. Linde-Zwirble, J.C. Marshall, and J. Bion The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis Crit Care Med 38 2010 367 374